dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorSanta Casa de Belo Horizonte
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2018-12-11T17:04:34Z
dc.date.available2018-12-11T17:04:34Z
dc.date.created2018-12-11T17:04:34Z
dc.date.issued2016-07-01
dc.identifierPharmacogenomics, v. 17, n. 10, p. 1121-1127, 2016.
dc.identifier1744-8042
dc.identifier1462-2416
dc.identifierhttp://hdl.handle.net/11449/173300
dc.identifier10.2217/pgs-2016-0033
dc.identifier2-s2.0-84979574365
dc.description.abstractAim: Over 40% of patients with pre-eclampsia are nonresponsive to antihypertensive therapy, but the underlying mechanisms are unknown. We examined the effects of plasma from nonresponsive and responsive patients on endothelial gene expression. Patients & methods: PCR array was performed in human umbilical vein endothelial cells (HUVEC) incubated with plasma from nonresponsive (n = 4) and responsive (n = 4) patients. Gene networks and interactions with antihypertensive drugs used in pre-eclampsia were identified by Ingenuity Pathway Analysis. Results: Nifedipine and hydralazine act by upregulate or downregulate genes found to be downregulated or upregulated in HUVEC incubated with plasma from nonresponsive patients. Conclusion: Our novel findings suggest that plasma from nonresponsive and responsive patients evoke different responses in HUVEC, and might advance the pharmacogenomics research in pre-eclampsia.
dc.languageeng
dc.relationPharmacogenomics
dc.relation0,845
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectantihypertensive drugs
dc.subjectgene expression
dc.subjecthuman umbilical vein endothelial cells
dc.subjecthydralazine
dc.subjectnifedipine
dc.subjectpathway analysis
dc.subjectPCR array
dc.subjectpharmacogenomics
dc.subjectpre-eclampsia
dc.titleAntihypertensive therapy in pre-eclampsia: Effects of plasma from nonresponsive patients on endothelial gene expression
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución